Bisubstrate Ether-Linked Uridine-Peptide Conjugates as O-GlcNAc Transferase Inhibitors.
Vivek MakwanaPhilip RyanAlpeshkumar K MaldeShailendra Anoopkumar-DukieSantosh RudrawarPublished in: ChemMedChem (2020)
The O-linked β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) is a master regulator of installing O-GlcNAc onto serine or threonine residues on a multitude of target proteins. Numerous nuclear and cytosolic proteins of varying functional classes, including translational factors, transcription factors, signaling proteins, and kinases are OGT substrates. Aberrant O-GlcNAcylation of proteins is implicated in signaling in metabolic diseases such as diabetes and cancer. Selective and potent OGT inhibitors are valuable tools to study the role of OGT in modulating a wide range of effects on cellular functions. We report linear bisubstrate ether-linked uridine-peptide conjugates as OGT inhibitors with micromolar affinity. In vitro evaluation of the compounds revealed the importance of donor substrate, linker and acceptor substrate in the rational design of bisubstrate analogue inhibitors. Molecular dynamics simulations shed light on the binding of this novel class of inhibitors and rationalized the effect of amino acid truncation of acceptor peptide on OGT inhibition.
Keyphrases
- molecular dynamics simulations
- transcription factor
- amino acid
- type diabetes
- cardiovascular disease
- signaling pathway
- squamous cell carcinoma
- molecular docking
- protein kinase
- skeletal muscle
- papillary thyroid
- drug delivery
- cancer therapy
- metabolic syndrome
- ionic liquid
- young adults
- energy transfer
- anti inflammatory
- squamous cell
- insulin resistance
- solar cells
- lymph node metastasis